<DOC>
	<DOCNO>NCT01483781</DOCNO>
	<brief_summary>The purpose study evaluate effect canagliflozin plasma volume renal parameter patient Type 2 Diabetes Mellitus currently take metformin treat high blood pressure .</brief_summary>
	<brief_title>A Study Effects Canagliflozin Plasma Volume Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>This double-blind ( neither patient study staff know identity treatment assign ) patient Type 2 Diabetes Mellitus ( T2DM ) inadequate glycemic ( blood sugar ) control metformin monotherapy ( metformin take alone control T2DM ) currently treat hypertension ( high blood pressure ) agent call angiotensin convert enzyme inhibitor ( ACEIs ) angiotensin receptor blocker ( ARBs ) . In study , patient randomize ( assigned chance ) receive treatment canagliflozin placebo ( treatment identical appearance canagliflozin contain active drug ) 12 week . During 12-week treatment period , patient also take metformin dose least 1500 mg/day addition prescribe ACEI ARB hypertension . Patients participate study approximately 22 week .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Canagliflozin</mesh_term>
	<mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
	<criteria>All patient must diagnosis T2DM inadequate glycemic control ( ie , HbA1c &gt; =7.0 % &lt; =9.0 % Screening ) metformin monotherapy receive therapy antihypertensive agent ( ACEI ARB ) least 4 week prior Screening History diabetic ketoacidosis , type 1 diabetes mellitus ( T1DM ) , pancreas beta cell transplantation , diabetes secondary pancreatitis pancreatectomy ; severe hypoglycemic episode within 6 month screen</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Diabetes Mellitus , Type 2</keyword>
	<keyword>Plasma Volume</keyword>
	<keyword>Canagliflozin</keyword>
	<keyword>Metformin</keyword>
	<keyword>Hemoglobin A1c</keyword>
	<keyword>Hypertension</keyword>
	<keyword>Angiotensin-Converting Enzyme Inhibitors ( ACEIs )</keyword>
	<keyword>Angiotensin Receptor Blockers ( ARBs )</keyword>
	<keyword>Pharmacodynamics</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>